Momentous Wealth Management Inc. Purchases New Shares in Johnson & Johnson (NYSE:JNJ)

Key Points

• Momentous Wealth Management Inc. has acquired a new stake in Johnson & Johnson, purchasing 1,523 shares valued at approximately $253,000. This acquisition reflects growing interest from institutional investors in the company.
• Analysts have mixed ratings on Johnson & Johnson, with ten analysts issuing a buy rating and two assigning a strong buy, while nine hold ratings are noted. The average target price for the stock is currently $174.50.
• The company announced a quarterly dividend of $1.30 per share, set to be paid on September 9th, yielding approximately 3.2% annually, with a dividend payout ratio of 55.61%.

Momentous Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 1,523 shares of the company's stock, valued at approximately $253,000.

Other large investors have also added to or reduced their stakes in the company. Conquis Financial LLC bought a new position in Johnson & Johnson during the 4th quarter valued at $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the 4th quarter valued at $36,000. Highline Wealth Partners LLC boosted its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. von Borstel & Associates Inc. bought a new position in Johnson & Johnson during the 1st quarter valued at $49,000. Finally, Capital A Wealth Management LLC bought a new position in Johnson & Johnson during the 4th quarter valued at $50,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on JNJ. UBS Group increased their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Nine analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Trading Down 1.5%

Shares of NYSE:JNJ opened at $164.76 on Friday. The company has a market cap of $396.81 billion, a PE ratio of 17.62, a P/E/G ratio of 2.13 and a beta of 0.41. The company's 50-day moving average price is $157.18 and its 200 day moving average price is $156.44. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the firm posted $2.82 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.2%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.